Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290313 | 0.80 | MAOB (0.62) | KDM4EALDH1A1LMNAHPGDMAPT | |
| SCHEMBL29831694 | 0.80 | MAOB (0.62) | KDM4EALDH1A1LMNAHPGDMAPT | |
| SCHEMBL12351964 | 0.77 | PARP1 (0.61) | KDM4EALDH1A1LMNAHPGDELANE | |
| SCHEMBL374735 | 0.75 | POLB (0.65) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL29367169 | 0.75 | POLB (0.65) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL111843 | 0.73 | POLB (0.62) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL29458312 | 0.73 | POLB (0.62) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL9066571 | 0.73 | POLB (0.62) | KDM4EALDH1A1HPGDL3MBTL1MAPT | |
| SCHEMBL203874 | 0.73 | MAPK14 (0.42) | KDM4EALDH1A1LMNAHPGDL3MBTL1 | |
| SCHEMBL11634021 | 0.68 | KDM4E (0.50) | KDM4EELANEMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | claimed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2019-05-09 | — | — | US | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| EP-2640395-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012064667-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-06-17 | — | — | US | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| EP-2130823-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-11207275-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-20220062194-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | KDM4E 2999/4885ALDH1A1 3953/4885LMNA 1402/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-20190134055-A1 | Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | KDM4E 838/4885ALDH1A1 886/4885LMNA 4648/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | KDM4E 2273/4885ALDH1A1 1653/4885LMNA 3687/4885 |
| US-20100152213-A1 | COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PDE4B, PDE7B, PDE12 | KDM4E 376/4885ALDH1A1 826/4885LMNA 4336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.